$11.62
3.38% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US26817R1086
Symbol
DYN

Dyne Therapeutics Inc Stock price

$11.62
+2.71 30.42% 1M
-2.30 16.52% 6M
-11.94 50.68% YTD
-31.45 73.02% 1Y
-0.43 3.57% 3Y
-12.28 51.38% 5Y
-12.28 51.38% 10Y
-12.28 51.38% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.38 3.38%
ISIN
US26817R1086
Symbol
DYN
Industry

Key metrics

Basic
Market capitalization
$1.6b
Enterprise Value
$1.0b
Net debt
positive
Cash
$683.9m
Shares outstanding
114.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
91.1%
Return on Equity
-50.4%
ROCE
-64.1%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-439.0m | $-445.6m
EBIT
$-440.9m | $-477.4m
Net Income
$-412.9m | $-460.8m
Free Cash Flow
$-361.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-62.9% | -30.2%
EBIT
-62.7% | -38.8%
Net Income
-60.3% | -45.2%
Free Cash Flow
-64.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.6
FCF per Share
$-3.2
Short interest
12.4%
Employees
191
Rev per Employee
$0.0
Show more

Is Dyne Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Dyne Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Dyne Therapeutics Inc forecast:

18x Buy
86%
3x Hold
14%

Analyst Opinions

21 Analysts have issued a Dyne Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Dyne Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
21% 21%
-
- Research and Development Expense 380 380
72% 72%
-
-439 -439
63% 63%
-
- Depreciation and Amortization 1.89 1.89
17% 17%
-
EBIT (Operating Income) EBIT -441 -441
63% 63%
-
Net Profit -413 -413
60% 60%
-

In millions USD.

Don't miss a Thing! We will send you all news about Dyne Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dyne Therapeutics Inc Stock News

Neutral
GlobeNewsWire
9 days ago
- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 -
Negative
The Motley Fool
15 days ago
Dyne Reports Wider Loss in Fiscal Q2
Neutral
GlobeNewsWire
15 days ago
- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne's first planned commercial launch in early 2027 -
More Dyne Therapeutics Inc News

Company Profile

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Head office United States
CEO John Cox
Employees 191
Founded 2017
Website dyne-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today